Nandrolone vs Phenylpiracetam
FDA Approved vs Moderate Research
monitor Mechanism-based · 51% Both Nandrolone and Phenylpiracetam can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar).
Molecular Data
Nandrolone Phenylpiracetam
Weight 274.40 Da (base) 218.25 Da
Half-life ~6-12 days (decanoate) ~3-5 hours
Type 19-nortestosterone steroid (C18H26O2) Racetam derivative (C12H14N2O2)
Key Benefits
Nandrolone
01 Significant increases in lean muscle mass with a favorable anabolic-to-androgenic ratio
02 Enhanced collagen synthesis and joint lubrication, reducing joint pain and improving connective tissue integrity
03 Increased bone mineral density through direct osteoblast stimulation
04 Improved nitrogen retention and protein synthesis for accelerated recovery
05 Stimulation of erythropoietin production, increasing red blood cell mass and oxygen delivery
06 Lower androgenic side effects (hair loss, acne, prostate enlargement) compared to testosterone
07 Clinically demonstrated efficacy in treating anemia of chronic renal failure
08 Potential neuroprotective properties observed in preclinical research
Phenylpiracetam
01 Potent cognitive enhancement including improved memory, focus, and information processing speed
02 Psychostimulant properties that increase motivation, mental energy, and alertness without the jitteriness of classical stimulants
03 Physical performance enhancement through improved stamina, reduced perception of effort, and increased exercise tolerance
04 Enhanced cold tolerance -- a unique property among nootropics, originally developed for extreme-environment performance
05 Anxiolytic effects at standard doses, reducing stress reactivity without sedation
06 Anticonvulsant activity demonstrated in preclinical models
Dosing Protocols
Nandrolone
100-200 mg/week (therapeutic) / 1x per week (decanoate) or 2-3x per week (NPP)
TRT Adjunct - Joint Support 50-100 mg/week 1x per week (decanoate)
Therapeutic - Anemia / Wasting 100-200 mg/week 1x per week (decanoate)
Performance Enhancement - Moderate 200-400 mg/week 1x per week (decanoate) or split into 2 injections
NPP Protocol - Shorter Cycle 200-350 mg/week Every other day or 3x per week
Phenylpiracetam
100-200 mg, 1-2x/day / Once or twice daily (morning, or morning and early afternoon)
Side Effects
Nandrolone
Suppression of natural testosterone production (profoundly suppressive, more so than testosterone alone)
Water retention and bloating (less than testosterone at equianabolic doses)
Erectile dysfunction and reduced libido without concurrent testosterone ('deca dick')
Increased appetite and weight gain
Mild acne and oily skin (less pronounced than testosterone)
Elevated hematocrit and hemoglobin (erythrocytosis)
Injection site pain or discomfort
Mild mood changes (some users report increased emotional sensitivity)
Phenylpiracetam
Insomnia, particularly if taken in the afternoon or evening -- the stimulant effects can persist for several hours after dosing
Irritability and overstimulation, especially at higher doses or when combined with other stimulants
Headache, most commonly caused by increased acetylcholine demand without adequate choline supplementation
Rapid tolerance development -- the most significant practical limitation, requiring intermittent dosing schedules to maintain efficacy
Contraindications
Prostate cancer (active or history of hormone-sensitive prostate cancer)
Breast cancer in males or females
Pregnancy or potential for pregnancy (Category X - causes virilization of female fetus)
Nephrosis or the nephrotic phase of nephritis
Severe hepatic impairment
Hypercalcemia
Known hypersensitivity to nandrolone or any formulation components
Polycythemia (hematocrit above 54% at baseline)
Uncontrolled heart failure or severe cardiovascular disease
Known hypersensitivity to phenylpiracetam or other racetams
Severe hypertension or cardiovascular disease (due to stimulant properties)
Pregnancy and breastfeeding (insufficient safety data)
Severe hepatic or renal impairment
Competitive athletes subject to WADA testing (phenylpiracetam is a prohibited substance under Section S6: Stimulants)
Research Evidence
Nandrolone Phenylpiracetam
Status FDA Approved Moderate Research
References 5 studies 5 studies
Latest April 2005 —
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.